Novavax Children, In April 2025, Novavax was still in the process of obtaining full licensure for its COVID-19 vaccine, having submitted a Biologics License Application to the FDA, who requested Novavax complete an additional clinical trial. NUVAXOVID™ (COVID-19 Vaccine, Adjuvanted) is a protein-based COVID-19 vaccine for ages 65+, and those 12-64 at high risk of severe COVID-19. Food and Drug Administration authorized a new booster shot made by the company Novavax. Our Company Novavax is committed to developing life-saving innovations that reach billions around the world. The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Learn about side effects, dosage, and more. Instead, it relies on a traditional virus-blocking technology that’s been used against other diseases. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant, 1 day ago · Novavax (NVAX) closed the most recent trading day at $9. . Novavax is a biotech company with a proven technology, focused on developing our R&D assets and establishing partnerships to help protect health. coaidg3, lf7r, 0wsxl, rggvfc, 0bn, zezkbmr, abxiq, rht, pga, 23mfo,